Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

3(60.0%)

N/A

2(40.0%)

5Total

Phase 1(3)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07109804Not ApplicableRecruiting

Cuneiform Nucleus (CnF) Deep Brain Stimulation for Gait Facilitation Following Spinal Cord Injury

Role: collaborator

NCT03999424Phase 1Completed

Autologous Human Schwann Cells in Peripheral Nerve Repair

Role: collaborator

NCT04050696Not ApplicableUnknown

The Use of Electromagnetic Field (EMF) Treatment in Chronic Spinal Cord Injury (SCI) Patients

Role: collaborator

NCT02510079Unknown

Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.

Role: collaborator

NCT02354625Phase 1Completed

The Safety of ahSC in Chronic SCI With Rehabilitation

Role: collaborator

NCT02480777Unknown

Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair

Role: collaborator

NCT01739023Phase 1Completed

Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI

Role: collaborator

All 7 trials loaded